Skip to main content

Multimodal Therapies for Nervous System Disorders: A Workshop

Completed

Multimodal therapy approaches (i.e., combinations of interventions aimed at different aspects of a disease) are emerging as potential ways to enhance clinical outcomes for patients with psychiatric and neurological disorders.The Forum on Neuroscience and Nervous System Disorders hosted a public workshop on June 14-15, 2016 that brought together key stakeholders to examine scientific, clinical, regulatory, and reimbursement issues related to multimodal approaches and identify potential opportunities to enhance clinical outcomes for individuals with nervous system disorders.

Description

An ad hoc committee will plan and conduct a 1.5-day public workshop to explore multimodal therapeutic approaches for nervous system disorders (i.e., combinations of interventions aimed at different aspects of a disease). This could include, for example, a drug prescribed along with a device, psychosocial intervention, lifestyle adjustment, or dietary intervention. The workshop will bring together key stakeholders to examine scientific, clinical, regulatory, and reimbursement issues related to multimodal approaches and identify potential opportunities to enhance clinical outcomes for individuals with nervous system disorders.

Invited presentations and discussions will be designed to:

  • Explore recent advances in the development of multimodal therapeutic approaches for nervous system disorders and approaches to using these therapies (e.g., earlier versus later in disease progression), and discuss future research needs to further advance understanding of these approaches.
  • Highlight disease areas in which a multimodal approach could be particularly useful (e.g., areas in which the pathophysiology is well understood).
  • Discuss methodologies for establishing efficacy for multimodal therapies compared to monotherapies, including clinical and statistical considerations.
  • Consider regulatory issues for multimodal therapies, including for approaches in which only one component is regulated (e.g., drug plus psychosocial intervention), and discuss potential opportunities for addressing challenges.
  • Consider reimbursement issues for multimodal therapies for nervous system disorders, and discuss potential opportunities for addressing challenges.
  • Incorporate lessons learned from other therapeutic areas in which multimodal approaches are more frequently used (e.g., diabetes, HIV, cancer).

The committee will develop the agenda for the workshop, select and invite speakers and discussants, and moderate the discussions. A summary of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.

Collaborators

Committee

Karl Kieburtz

Co-Chair

Sarah H. Lisanby

Co-Chair

Robert C. Alexander

Member

Timothy Denison

Member

James A. Hendrix

Member

Thinh Nguyen

Member

David Shurtleff

Member

Timothy J. Strauman

Member

Stevin H. Zorn

Member

Sponsors

Department of Health and Human Services

National Science Foundation

Staff

Clare Stroud

Lead

Sheena Posey Norris

Major units and sub-units

Institute of Medicine

Lead

Board on Health Sciences Policy

Lead

Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.